Placebo-SC

DRUG2 trials

Sponsors

Eli Lilly and Company, Allakos Inc.

Conditions

Chronic Spontaneous UrticariaHealthy ParticipantsOsteoporosis

Phase 1

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

CompletedNCT06072157

Allakos Inc.Chronic Spontaneous Urticaria, Healthy Participants

Start: 2023-08-28End: 2025-05-12Updated: 2025-06-03

Phase 4

The Forteo Alendronate Comparator Trial

CompletedNCT02416271

Eli Lilly and CompanyOsteoporosis

Start: 2001-04-30End: 2003-05-31Updated: 2015-04-14